Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Fingolimod (Gilenya) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients

Next Previous
Trial Profile

Effects of Fingolimod (Gilenya) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 24 May 2017 Status changed from recruiting to completed.
  • 14 Oct 2015 Planned end date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
  • 14 Oct 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top